Adil Abbasi, MD FACP

Learning Objectives: After completing this chapter, the reader should be able to:

• Describe the major complications of liver cirrhosis.
• Understand the pathophysiology underlying each complication.
• Recognize the typical sequence of decompensation in cirrhosis.
• Explain the morbidity and mortality associated with various complications.
• Diagnose and manage portal hypertension and its consequences.
• Understand the clinical significance of pancytopenia, coagulopathy, and hypoalbuminemia.
• Recognize when referral for liver transplantation is indicated.
• Apply evidence-based approaches to the prevention and management of cirrhosis complications.

Introduction: Liver cirrhosis represents the end stage of chronic liver disease characterized by diffuse hepatic fibrosis, regenerative nodule formation, and distortion of normal hepatic architecture. The progression from compensated cirrhosis to decompensated cirrhosis marks a major transition associated with significantly increased morbidity, mortality, healthcare utilization, and reduced quality of life.

The major complications of cirrhosis arise from two principal mechanisms: progressive hepatic insufficiency and portal hypertension. These complications rarely occur simultaneously at disease onset but instead develop progressively over time. Recognition of these complications is critical because their appearance frequently identifies patients who should undergo evaluation for liver transplantation.

Compensated cirrhosis may remain clinically silent for years. Once decompensation develops, median survival declines substantially, often from greater than 12 years to approximately 2 years depending on the severity and number of complications.

Pathophysiology: The complications of cirrhosis result from a combination of:

• Portal hypertension
• Reduced synthetic liver function
• Impaired detoxification capacity
• Altered immune function
• Systemic inflammation
• Hemodynamic abnormalities
• Renal dysfunction

Portal hypertension develops when fibrosis increases resistance to portal venous blood flow. Portal pressures progressively rise, causing collateral vessel formation, splenomegaly, varices, ascites, and portal hypertensive gastropathy. Simultaneously, loss of functioning hepatocytes leads to reduced synthesis of:

• Albumin
• Clotting factors
• Complement proteins
• Carrier proteins

As liver disease progresses, multiple organ systems become affected, producing the characteristic complications of advanced cirrhosis.

Natural History: Typical Order of Complications: Although substantial variability exists among individual patients, complications often develop in the following general sequence:

Early Compensated Cirrhosis

• Portal hypertension
• Splenomegaly
• Mild thrombocytopenia
• Mild coagulopathy
• Small esophageal varices

Early Decompensation

• Clinically significant varices
• Ascites
• Peripheral edema
• Hypoalbuminemia

Advanced Decompensation

• Refractory ascites
• Hepatic encephalopathy
• Spontaneous bacterial peritonitis
• Hepatorenal syndrome
• Severe coagulopathy
• Severe pancytopenia

End-Stage Disease

• Recurrent variceal hemorrhage
• Recurrent encephalopathy
• Refractory ascites
• Multi-organ failure
• Hepatocellular carcinoma
• Death

Portal Hypertension: Portal hypertension is the fundamental driver of most cirrhosis complications. Clinically significant portal hypertension is generally defined as a hepatic venous pressure gradient exceeding 10 mmHg.

Portal hypertension causes:

• Esophageal varices
• Gastric varices
• Ascites
• Splenomegaly
• Portal hypertensive gastropathy
• Hepatic hydrothorax
• Hepatorenal syndrome

Portal hypertension itself is associated with increasing mortality as portal pressures rises.

Esophageal and Gastric Varices

Pathophysiology: Varices develop when portal hypertension forces blood through collateral venous channels. Varices may enlarge progressively over years. The most clinically important sites are:

• Distal esophagus
• Gastric fundus
• Rectum

Clinical Presentation: Most patients remain asymptomatic until bleeding occurs. Variceal hemorrhage presents with:

• Hematemesis
• Melena
• Hematochezia
• Syncope
• Shock

Morbidity and Mortality: Variceal hemorrhage remains one of the most feared complications of cirrhosis. Historically, mortality exceeded 40%. Current mortality remains approximately 15–20% despite modern therapy. Each bleeding episode significantly increases future mortality risk.

Management: Primary prevention includes:

• Non-selective beta blockers
• Endoscopic variceal ligation

Acute bleeding requires:

• ICU-level care
• Octreotide
• Antibiotics
• Endoscopic intervention
• TIPS when necessary

Ascites: Ascites is the most common complication of cirrhosis. Approximately 50% of patients with compensated cirrhosis develop ascites within 10 years. The appearance of ascites indicates decompensated liver disease. Median survival decreases substantially after ascites develops. Complications include:

• Spontaneous bacterial peritonitis
• Hepatorenal syndrome
• Respiratory compromise
• Umbilical hernias
• Hepatic hydrothorax

Management includes sodium restriction, diuretics, paracentesis, TIPS, and transplantation.

Hepatic Encephalopathy:

Pathophysiology: Hepatic encephalopathy results from accumulation of neurotoxins, particularly ammonia, due to impaired hepatic detoxification and portosystemic shunting.

Clinical Presentation: Manifestations include:

• Sleep disturbances
• Personality changes
• Memory impairment
• Confusion
• Asterixis
• Coma

Morbidity and Mortality: Hepatic encephalopathy significantly impairs quality of life. Recurrent episodes are associated with:

• Increased hospitalization
• Cognitive decline
• Increased mortality

One-year survival decreases substantially after recurrent encephalopathy develops.

Management: Treatment includes:

• Lactulose
• Rifaximin
• Correction of precipitating factors
• Nutritional optimization

Splenomegaly and Pancytopenia

Pathophysiology: Portal hypertension causes splenic congestion and enlargement. This leads to hypersplenism and excessive sequestration of blood cells. Affected cell lines include:

• Platelets
• White blood cells
• Red blood cells

Thrombocytopenia: Thrombocytopenia is often the earliest laboratory abnormality in cirrhosis. Contributing factors include:

• Splenic sequestration
• Reduced thrombopoietin production

Platelet counts frequently fall below 100,000/mm³. Severe thrombocytopenia increases procedural bleeding risk.

Leukopenia: Leukopenia predisposes patients to infection. Immune dysfunction further compounds infection risk.

Anemia: Causes include:

• Hypersplenism
• Gastrointestinal bleeding
• Nutritional deficiencies
• Bone marrow suppression

Morbidity and Mortality: Pancytopenia contributes to:

• Bleeding complications
• Infections
• Fatigue
• Hospitalization

Severity generally correlates with advanced portal hypertension.

Management: Management focuses on:

• Treating portal hypertension
• Managing bleeding sources
• Correcting deficiencies
• Considering TIPS in selected patients

Coagulopathy

Pathophysiology: The liver synthesizes most clotting factors including:

• II
• V
• VII
• IX
• X
• XI

Progressive liver dysfunction reduces production of these factors. PT and INR become prolonged.

However, cirrhosis produces a complex "rebalanced hemostasis" rather than simple bleeding tendency. Both bleeding and thrombosis risks increase.

Clinical Significance: Manifestations include:

• Easy bruising
• Procedural bleeding
• Gastrointestinal hemorrhage

Paradoxically, cirrhotic patients may also develop:

• Portal vein thrombosis
• Deep venous thrombosis
• Pulmonary embolism

Morbidity and Mortality: Marked coagulopathy usually indicates advanced hepatic failure and worsens prognosis.

Management: Management includes:

• Treating underlying liver disease
• Vitamin K when appropriate
• Blood products only when clinically indicated
• Thromboelastographic-guided correction in complex cases

Hypoalbuminemia

Pathophysiology: Albumin synthesis occurs exclusively within hepatocytes. Progressive cirrhosis reduces albumin production. Normal serum albumin is approximately 3.5–5.0 g/dL. Hypoalbuminemia contributes to reduced plasma oncotic pressure and fluid accumulation.

Clinical Manifestations: Hypoalbuminemia contributes to:

• Ascites
• Peripheral edema
• Muscle wasting
• Frailty
• Poor wound healing

Morbidity and Mortality: Serum albumin is one of the strongest predictors of survival in cirrhosis. Lower albumin levels correlate with:

• Increased hospitalization
• Increased infection risk
• Increased mortality

Management: Management includes:

• Treatment of liver disease
• Nutritional optimization
• Albumin replacement in selected clinical situations

Spontaneous Bacterial Peritonitis: SBP is a bacterial infection of ascitic fluid occurring without a surgically correctable source. Mortality remains approximately 20–30% despite treatment. Complications include:

• Septic shock
• Renal failure
• Hepatorenal syndrome
• Encephalopathy
• Death

Management includes:

• Third-generation cephalosporins
• Albumin
• Secondary prophylaxis

Hepatorenal Syndrome

Pathophysiology: Severe splanchnic vasodilation leads to profound renal vasoconstriction and progressive renal failure. The kidneys themselves are structurally normal.

Clinical Significance: Hepatorenal syndrome is among the deadliest complications of cirrhosis. Untreated median survival may be measured in weeks.

Management: Treatment includes:

• Albumin
• Vasoconstrictors
• TIPS in selected patients
• Liver transplantation

Hepatocellular Carcinoma

Pathophysiology: Cirrhosis is the strongest risk factor for hepatocellular carcinoma.

Annual incidence ranges from approximately 1–6% depending on etiology.

Morbidity and Mortality. HCC is a leading cause of death among cirrhotic patients.

Survival depends heavily upon early detection.

Surveillance: Recommended surveillance includes:

• Ultrasound every six months
• AFP testing when appropriate

Infection and Immune Dysfunction: Cirrhosis produces a state of cirrhosis-associated immune dysfunction. Infection is among the most common precipitating causes of hospitalization and death. Common infections include:

• SBP
• Pneumonia
• Urinary tract infection
• Cellulitis
• Bacteremia

Overall Morbidity and Mortality by Major Complication

Liver Transplantation: Development of any of the following should prompt transplantation evaluation:

• Ascites
• Refractory ascites
• Variceal hemorrhage
• Hepatic encephalopathy
• SBP
• Hepatorenal syndrome
• Hepatocellular carcinoma

Liver transplantation remains the only definitive treatment for decompensated cirrhosis.

Summary

• Cirrhosis complications arise primarily from portal hypertension and hepatic insufficiency.
• Thrombocytopenia is often the earliest detectable complication.
• Portal hypertension leads to varices, splenomegaly, ascites, and hypersplenism.
• Ascites is the most common decompensating event.
• Variceal bleeding remains one of the most lethal acute complications.
• Pancytopenia results primarily from hypersplenism and reduced hepatic synthetic function.
• Coagulopathy reflects impaired synthesis of clotting factors but does not eliminate thrombotic risk.
• Hypoalbuminemia contributes significantly to edema, ascites, frailty, and mortality.
• Hepatic encephalopathy, SBP, and hepatorenal syndrome indicate advanced disease.
• Hepatocellular carcinoma remains a major cause of death in cirrhotic patients.
• The appearance of decompensating complications should trigger consideration of liver transplantation.

References

Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. (2008). Portal hypertension and gastrointestinal bleeding. Seminars in Liver Disease, 28(1), 3–25.

D'Amico G, Garcia-Tsao G, Pagliaro L. (2006). Natural history and prognostic indicators of survival in cirrhosis. Journal of Hepatology, 44(1), 217–231.

European Association for the Study of the Liver (EASL). (2018). Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 69(2), 406–460.

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. (2017). Portal hypertensive bleeding in cirrhosis. Hepatology, 65(1), 310–335.

Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. (2021). Liver cirrhosis. The Lancet, 398(10308), 1359–1376.

Runyon BA. (2009). Management of adult patients with ascites due to cirrhosis. Hepatology, 49(6), 2087–2107.

Schuppan D, Afdhal NH. (2008). Liver cirrhosis. The Lancet, 371(9615), 838–851.

Tsochatzis EA, Bosch J, Burroughs AK. (2014). Liver cirrhosis. The Lancet, 383(9930), 1749–1761.

Villanueva C, Albillos A, Genescà J, et al. (2016). Beta blockers to prevent decompensation of cirrhosis. New England Journal of Medicine, 376(7), 633–643.

Wiest R, Lawson M, Geuking M. (2014). Pathological bacterial translocation in liver cirrhosis. Journal of Hepatology, 60(1), 197–209.